BIIB Stock Recent News

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA

The Genetic Toxicology Testing market is expected to rise due to rising genetic disease incidence, advancements in genetic toxicology testing technologies, increased R&D activities, strategic collaborations, and a focus on personalized therapy. The Genetic Toxicology Testing market is expected to rise due to rising genetic disease incidence, advancements in genetic toxicology testing technologies, increased R&D activities, strategic collaborations, and a focus on personalized therapy.

Billionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world's most successful alternative investment firms.

Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option

Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.

Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB, ETR:IDP). Biogen has proposed to acquire all of Sage's shares that it does not already own for $7.22 per share.

Sage Therapeutics + Biogen -0.36 (-0.24%)

Biogen -1.98 (-1.31%) Sage Therapeutics -0.29 (-4.96%)